Shoshana Lipson, a patient advocate and founder of the “CGRP & Migraine Community ” on Facebook explains what she sees as the biggest takeaways from the migraine peer exchange that she participated in.
Transcript:
What were the biggest takeaways from the migraine peer exchange that you participated in?
So, I would say that the biggest takeaway that I have from the peer exchange today would be that there's hope on all sides. I think especially on the physician side but also from the employer side and the payer side. We're now dealing with a new situation because of this new frontier in migraine treatment and so it is just generating a lot of interest and a lot of hope on every side.
It was also highlighted to me that the situation is complex. Not only getting access to the medications but getting them improved by the insurance companies, bringing employers into the conversation as well, that it's not an easy process, and that each side doesn't necessarily know where the other side is at, so improving communications for all of these branches is huge.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More